NRG Therapeutics expands team with CDO appointment – The Pharma Letter

UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO).
In his role at NRG, Mr Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.
NRG5051 is an oral, CNS-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP) acting via a novel mechanism of action (MoA). Inhibition of the mPTP has been shown to be profoundly neuroprotective and significantly reduces neuroinflammation in pre-clinical models of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), and Parkinson’s. He will also take responsibility for all non-clinical development functions within NRG.
This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
7 day trial access
Become a subscriber
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
The Pharma Letter
39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom
Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.